TESARO (TSRO) – Press Releases
-
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of BSB Bancorp, Gaming Partners, Tribune Media, and Tesaro on Behalf of Stockholders and Encourages Inves
-
TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes
-
TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes
-
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Tesaro, Inc. (TSRO) on Behalf of Stockholders and Encourages TSRO Investors to Contact the Firm
-
Detailed Research: Economic Perspectives on TESARO, Regeneron Pharmaceuticals, Pool, Zebra Technologies, Cadence Design, and TherapeuticsMD — What Drives Growth in Today's Competitive Landscape
-
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
-
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
-
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
-
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
-
TESARO Announces Third-Quarter 2018 Operating Results
-
TESARO Announces Third-Quarter 2018 Operating Results
-
The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year
-
The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year
-
TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen
-
TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen
-
TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community
-
TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community
-
TESARO Announces Data Presentations at ESMO 2018 Congress
-
TESARO Announces Data Presentations at ESMO 2018 Congress
-
TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018
-
TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018
-
TESARO Announces Data Presentations at the ESMO 2018 Congress
-
TESARO Announces Data Presentations at the ESMO 2018 Congress
-
TESARO Announces Data Presentations at the SITC 2018 Annual Meeting
-
TESARO Announces Data Presentations at the SITC 2018 Annual Meeting
-
TESARO Announces Participation at Two Investor Conferences
-
TESARO Announces Participation at Two Investor Conferences
-
TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer
-
TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer
-
TESARO Announces Participation at Three Investor Conferences
-
TESARO Announces Participation at Three Investor Conferences
-
TESARO Announces Second-Quarter 2018 Operating Results
-
TESARO Announces Second-Quarter 2018 Operating Results
-
TESARO to Announce Second-Quarter 2018 Financial Results on August 2, 2018
-
TESARO to Announce Second-Quarter 2018 Financial Results on August 2, 2018
-
TESARO Partners With the Pan-Mass Challenge for 2018 Ride Benefiting Dana-Farber Cancer Institute
-
TESARO Partners With the Pan-Mass Challenge for 2018 Ride Benefiting Dana-Farber Cancer Institute
-
TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing
-
TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing
-
TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada
-
TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada
-
TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
-
TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
-
TESARO Summarizes TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting
-
TESARO Summarizes TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting
-
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
-
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
-
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
-
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
-
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Back to TSRO Stock Lookup